23804-68-4

Usage

Uses

Used in Pharmaceutical Industry:
4-(aminomethyl)-1-benzylpiperidin-4-ol is used as a medication for the treatment of pancreatitis, a condition characterized by inflammation of the pancreas, and disseminated intravascular coagulation (DIC), a serious disorder that affects the body's blood clotting system.
Used in COVID-19 Treatment:
4-(aminomethyl)-1-benzylpiperidin-4-ol is used as a potential treatment for COVID-19, as it has been found to inhibit the replication of the virus in vitro, offering a promising therapeutic approach against the disease.
Used in Blood Coagulation Prevention:
4-(aminomethyl)-1-benzylpiperidin-4-ol is used as an agent for preventing blood coagulation, which can help in managing and treating conditions associated with abnormal blood clotting.
Used in Anti-Inflammatory Applications:
4-(aminomethyl)-1-benzylpiperidin-4-ol is used as an anti-inflammatory agent, potentially providing relief from inflammation and associated symptoms in various medical conditions.

Upstream product

• 19867-34-6 N-benzyl-1-oxa-6-azaspiro[2,5]-octane 
• 3612-20-2 1-phenylmethyl-4-piperidone 
• 6094-60-6 1-benzyl-4-hydroxypiperidine-4-carbonitrile 
• 7677-24-9 trimethylsilyl cyanide 
• 156215-49-5 1-benzyl-4-(trimethylsilyloxy)piperidine-4-carbonitrile 

Downstream Products

• 5053-14-5 8-Benzyl-1-oxa-3,8-diaza-spiro[4.5]decan-2-one 
• 318986-28-6 8a-[(acetyloxy)methyl]-7-[(6-chloro-2-naphthalenyl)sulfonyl]tetrahydro-1'-benzyl-spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidin]-5-one 
• 911834-47-4 tert-butyl (+/-)-tetrahydro-5-oxo-1'-(phenylmethyl)-8a-(phthalimid-1-ylmethyl)spiro[5H-oxazolo[3,2-a]pyrazine-2(3H),4'-piperidine]-7-carboxylate 
• 23804-77-5 8-(4-nitro-phenethyl)-1-oxa-3,8-diaza-spiro[4.5]decan-2-one 
• 23804-80-0 8-(4-amino-phenethyl)-1-oxa-3,8-diaza-spiro[4.5]decan-2-one 
• 5052-95-9 1-oxa-3,8-diazaspiro[4.5]-decan-2-one 
• 23866-35-5 N,N-dimethyl-4-[2-(2-oxo-1-oxa-3,8-diaza-spiro[4.5]dec-8-yl)-ethyl]-benzenesulfonamide 
• 5053-04-3 N-(4-ethoxy-phenyl)-2-(2-oxo-1-oxa-3,8-diaza-spiro[4.5]dec-8-yl)-acetamide 
• 5053-02-1 8-(3-trifluoromethyl-phenethyl)-1-oxa-3,8-diaza-spiro[4.5]decan-2-one 
• 5229-89-0 8-(2-benzo[1,3]dioxol-5-yl-ethyl)-1-oxa-3,8-diaza-spiro[4.5]decan-2-one 
• 6094-61-7 8-benzhydryl-1-oxa-3,8-diaza-spiro[4.5]decan-2-one 
• 5229-85-6 8-(2-hydroxy-3-phenyl-propyl)-1-oxa-3,8-diaza-spiro[4.5]decan-2-one 

Relevant academic research and scientific papers

COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES

The present invention provides a compound of formula (Ia) or a pharmaceutically acceptable salt thereof; a method for manufacturing the compounds of the invention, solid forms, combinations of pharmacologically active agents, pharmaceutical compositions and methods of using such compounds and solid forms thereof to treat or prevent parasitic diseases, for example malaria.

ANTIMICROBIAL COMPOUNDS AND METHODS

The invention is directed to compounds that are active as antibacterial agents. The invention compounds are active against gram-positive and gram-negative bacteria and can be used to treat infections caused by gram-positive and gram-negative bacteria. Also disclosed are processes and intermediates for making the compounds.

SUBSTITUTED PYRIDINES AS INHIBITORS OF DNMT1

The invention is directed to substituted pyridine derivatives. Specifically, the invention is directed to compounds according to Formula (Iar): (Iar) wherein Yar, X1ar, X2ar, R1ar, R2ar, R3ar, R4ar and R5ar are as defined herein; or a pharmaceutically acceptable salt or prodrug thereof. The compounds of the invention are selective inhibitors of DNMT1 and can be useful in the treatment of cancer, pre-cancerous syndromes, beta hemoglobinopathy disorders, sickle cell disease, sickle cell anemia, and beta thalassemia, and diseases associated with DNMT1 inhibition. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting DNMT1 activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

Spirocyclic derivatives

The present invention provides compounds of formula (I): compositions comprising such compounds; the use of such compounds in therapy (for example in the treatment or prevention of a disease, disorder or condition ameliorated by inhibition of a dopamine transporter); and methods of treating patients with such compounds; wherein R1, R2, R3, R4, R5, R6, R9, R10, Q, X, Y, Z, A, L, B, m, n and p are as defined herein.

N-(HETERO)ARYL-SUBSTITUTED HETEROYCLIC DERIVATIVES USEFUL FOR THE TREATMENT OF DISEASES OR CONDITIONS RELATED TO THE CENTRAL NERVOUS SYSTEM

The present invention provides compounds of formula (I): compositions comprising such compounds; the use of such compounds in therapy (for example in the treatment or prevention of a disease, disorder or condition ameliorated by inhibition of a dopamine transporter); and methods of treating patients with such compounds; wherein R1, R2, R3, R4, R9a, R9b, R9c, R9d, R9e, R9f, m, n, A, L and B are as defined herein.

2-[BIS(4-FLUOROPHENYL)METHYL]-2,7-DIAZASPIRO[4.5]DECAN-10-ONE DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF THE HUMAN DOPAMINE-ACTIVE-TRANSPORTER (DAT) PROTEIN FOR THE TREATMENT OF E.G. ATTENTION DEFICIT DISORDER (ADD)

The present invention provides compounds of formula (I) and in particular 2-[bis(4-fluorophenyl)methyl]-2,7- diazaspiro[4.5]decan-10-one derivatives and related compounds as inhibitors of human dopamine-active-transporter (DAT) protein for the treatment of sexual dysfunction, affective disorders, anxiety, depression, chronic fatigue, Tourette syndrome, Angelman syndrome, attention deficit disorder (ADD), attention deficit hyperactivity disorder (ADHD), obesity, pain, obsessive-compulsive disorder, movement disorders, CNS disorders, sleep disorders, narcolepsy, conduct disorder, substance abuse (including smoking cessation), eating disorders, and impulse control disorders.

ALKYL AND ARYL DERIVATIVES OF 1-OXA-4,9-DIAZASPIRO UNDECANE COMPOUNDS HAVING MULTIMODAL ACTIVITY AGAINST PAIN

The present invention relates to compounds of general formula (I) having dual pharmacological activity towards both the sigma (σ) receptor, and the μ-opiod receptor and more particularly to diazaspiro undecane compounds having this pharmacological activity, to processes of preparation of such compounds, to pharmaceutical compositions comprising them, and to their use in therapy, in particular for the treatment of pain.

Delayed and prolonged histone hyperacetylation with a selective HDAC1/HDAC2 inhibitor

The identification and in vitro and in vivo characterization of a potent SHI-1:2 are described. Kinetic analysis indicated that biaryl inhibitors exhibit slow binding kinetics in isolated HDAC1 and HDAC2 preparations. Delayed histone hyperacetylation and

PIPERIDINE-CONTAINING COMPOUNDS AND USE THEREOF

A method for preventing and/or treating a metabolic disease, cerebrovascular disease, etc. which comprises administering to a mammal an effective amount of the compound of the formula (I) wherein all symbols have the same meanings as defined in the specification; a salt thereof, an N-oxide thereof, a solvate thereof, or a prodrug thereof. And a novel compound of the formula (I-1): wherein all symbols have the same meanings as defined in the specification; a salt thereof, an N-oxide thereof, a solvate thereof, or a prodrug thereof has an anti-diabetic effect and a neuroprotective effect. Accordingly, the compound of the formula (I) and the compound of the formula (I-1) are useful in a method for preventing and/or treating for a metabolic disease such as diabetes, cerebrovascular disease such as stroke, etc.

N,N'-2,4-DIANILINOPYRIMIDINE DERIVATIVES, PREPARATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS ESSENTIALLY AS IKK INHIBITORS

The disclosure relates to a compound of formula (I): wherein R, R1, R2, R3, R4, R5, R6 and Z are as defined in the specification, to compositions containing them, to processes for preparing them, and to their use in the treatment or prevention of conditio